GALT
Galectin Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.61
+5.98%Aug 14, 2026, 12:00 UTC
Galectin Therapeutics reported financial results for the three months ended June 30, 2026, and provided a business update.
Source:Aug 4, 2026, 12:00 UTC
Galectin Therapeutics announced that Chairman Richard E. Uihlein converted approximately $105.8 million of outstanding debt under five line of credit facilities into common stock, eliminating the debt and increasing market capitalization.
Source:Jun 24, 2026, 15:06 UTC
Galectin Therapeutics received FDA alignment on key elements of belapectin's Phase III MASH cirrhosis program, clarifying a potential path toward full approval.
Source:Jun 23, 2026, 12:00 UTC
Galectin Therapeutics received positive feedback from a Type C meeting with the FDA supporting the advancement of belapectin for MASH cirrhosis and portal hypertension.
Source: